- Home
- LYRA vs KPRX Comparison
LYRA vs KPRX Comparison
Compare LYRA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- KPRX
- Stock Information
- Founded
- LYRA 2005
- KPRX 1998
- Country
- LYRA United States
- KPRX United States
- Employees
- LYRA N/A
- KPRX N/A
- Industry
- LYRA Medical/Dental Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LYRA Health Care
- KPRX Health Care
- Exchange
- LYRA Nasdaq
- KPRX Nasdaq
- Market Cap
- LYRA 11.3M
- KPRX 9.2M
- IPO Year
- LYRA 2020
- KPRX N/A
- Fundamental
- Price
- LYRA $6.41
- KPRX $2.65
- Analyst Decision
- LYRA Hold
- KPRX Strong Buy
- Analyst Count
- LYRA 1
- KPRX 1
- Target Price
- LYRA $16.00
- KPRX $10.00
- AVG Volume (30 Days)
- LYRA 14.8K
- KPRX 26.7K
- Earning Date
- LYRA 11-11-2025
- KPRX 11-07-2025
- Dividend Yield
- LYRA N/A
- KPRX N/A
- EPS Growth
- LYRA N/A
- KPRX N/A
- EPS
- LYRA N/A
- KPRX N/A
- Revenue
- LYRA $770,000.00
- KPRX N/A
- Revenue This Year
- LYRA N/A
- KPRX N/A
- Revenue Next Year
- LYRA $123.46
- KPRX N/A
- P/E Ratio
- LYRA N/A
- KPRX N/A
- Revenue Growth
- LYRA N/A
- KPRX N/A
- 52 Week Low
- LYRA $3.81
- KPRX $2.25
- 52 Week High
- LYRA $37.50
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- LYRA 38.58
- KPRX 46.53
- Support Level
- LYRA $6.15
- KPRX $2.58
- Resistance Level
- LYRA $6.72
- KPRX $2.80
- Average True Range (ATR)
- LYRA 0.38
- KPRX 0.11
- MACD
- LYRA -0.01
- KPRX -0.01
- Stochastic Oscillator
- LYRA 25.85
- KPRX 21.88
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.